AngenMed Therapeutics, Inc.

Redefining Cancer Treatment with Breakthrough Immunotherapy

About Us

Every Patient Deserves Our Best Effort for a Cure

AngenMed is dedicated to making a meaningful impact on delivering life-changing treatment to patients by developing Neo-Antigen Targeting cell-based therapies. Our mission is to deliver breakthrough innovations by leveraging the human immune system's power to identify and combat various cancer cells unique to each patient

Immunotherapy is the forefront of cancer therapy

There are several approaches to cancer treatment, including hormone therapy, surgery, bone marrow transplantation, chemotherapy, targeted therapy, and radiation therapy. These treatments work to destroy cancer cells but may also harm healthy cells, causing side effects. Moreover, existing therapies often encounter issues such as drug resistance and cancer recurrence, affecting their long-term effectiveness

Chemotherapy
Hormone Therapy
Radiation Therapy
Bone Marrow Transplantation
Surgery
Targeted Therapy

Immunotherapy is now the cornerstone of cancer treatment, leveraging our body’s immune system to target and destroy cancers.

Neoantigens: The Cornerstone of Cutting-Edge Immune Cancer Therapy

Neoantigens are unique markers that appear on cancer cells because of changes (mutations) in their DNA. These mutations create new, abnormal proteins not found in healthy cells. The body's immune system can recognize these markers as "foreign" because they are different from the normal proteins in the body.
T cells, which are part of the immune system, can detect these neoantigens. They bind to the neoantigens displayed on the surface of cancer cells, which signals the T cells to attack and destroy the cancer cells.
Neoantigens are better targets for cancer treatment because they are unique to cancer cells and do not exist in healthy cells. This means treatments that focus on neoantigens are more precise, reducing the risk of harming normal cells and making them a powerful tool for personalized cancer therapies.

Neoantigens are unique markers that appear on cancer cells because of changes (mutations) in their DNA. These mutations create new, abnormal proteins not found in healthy cells. The body's immune system can recognize these markers as "foreign" because they are different from the normal proteins in the body.

T cells, which are part of the immune system, can detect these neoantigens. They bind to the neoantigens displayed on the surface of cancer cells, which signals the T cells to attack and destroy the cancer cells.
Neoantigens are better targets for cancer treatment because they are unique to cancer cells and do not exist in healthy cells. This means treatments that focus on neoantigens are more precise, reducing the risk of harming normal cells and making them a powerful tool for personalized cancer therapies.

ANG-NeoSync® Platform
Best-in-Class Immunotherapy

DC vaccine/T cell Products towards Comprehensive Tumor NeoAgs
Enhanced Specificity and Function of CD8+/CD4+ T Cell Products
Higher Yields of Cell Products, Dose Expansion, Stability, and Functionality in Manufacturing Plants

Our Next Generation Immunotherapy

AGT-NeoSync® Platform

A Tailored, Multi-targeted, Cancer-specific Solution to Overcome Current Limitations and Maximize Therapeutic Potential

Key Steps in the Process

Mutations Identification
NeoAgs mRNA Generation
Dendritic cells+ T cells Generation
Cell Product Ready-to-use

Advantages of Our Solutions

Tumor-specific, no damage to normal tissue
Broadly applicable in multiple tumor types
Comprehensive NeoAgs targeting to reduce the risk of escape and potentially improve clinical benefits
Personalized therapeutic strategy

R&D Pipeline

AGT-NeoAgs panel

We identify neoantigens by analyzing mutations in the tumor using sequencing technology. These neoantigens are then used to create a NeoAg mRNA vaccine. At the same time, we collect blood samples from patients to isolate dendritic cells (DC) and T cells, which are then cultured to produce NeoPrime DC and NeoBoost T-cells.

AGT-NeoPrime® DC

Instead of directly injecting the vaccine into the body, we load the NeoAgs vaccine onto cultured DC. DC acts as a "trainer" for T cells. They process the neoantigens and train T cells to recognize and attack the "enemy". (the cancer cells marked by neoantigens)

AGT-NeoBoost® T-cells